Molecular Biology

, Volume 51, Issue 6, pp 769–771 | Cite as

Antibody-Based Drugs and Other Recombinant Proteins for Diagnostics and Therapy of Viral Infections, Autoimmune Diseases and Cancer

Current Trends in the Application of Monoclonal Antibodies Special Issue


immunoglobulins catalytic antibodies chimeric antigenic receptors targeted therapy immunotherapy targeted delivery 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Khler G., Milstein C. 1975. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 256, 495–497.CrossRefGoogle Scholar
  2. 2.
    Beck A., Wurch T., Bailly C., et al. 2010. Strategies and challenges for the next generation of therapeutic antibodies. Nat. Rev. Immunol. 10, 345–352.CrossRefPubMedGoogle Scholar
  3. 3.
    Hou X.L., Wang L., Ding Y.L., et al. 2016. Current status and recent advances of next generation sequencing techniques in immunological repertoire. Genes Immun. 17, 153–164.CrossRefPubMedGoogle Scholar
  4. 4.
    Grzelczak M., Vermant J., Furst E.M., et al. 2010. Directed self-assembly of nanoparticles. ACS Nano. 4, 3591–3605.CrossRefPubMedGoogle Scholar
  5. 5.
    Russell C.J. 2011. Stalking influenza diversity with a universal antibody. N. Engl. J. Med. 365, 1541–1542.CrossRefPubMedGoogle Scholar
  6. 6.
    Pabst O. 2012. New concepts in the generation and functions of IgA. Nat. Rev. Immunol. 12, 821–832.CrossRefPubMedGoogle Scholar
  7. 7.
    Kwong P.D., Mascola J.R., Nabel G.J. 2013. Broadly neutralizing antibodies and the search for an HIV-1 vaccine: The end of the beginning. Nat. Rev. Immunol. 13, 693–701.CrossRefPubMedGoogle Scholar
  8. 8.
    Lerner R.A., Benkovic S.J., Schultz P.G. 1991. At the crossroads of chemistry and immunology: Catalytic antibodies. Science. 252, 659–667.CrossRefPubMedGoogle Scholar
  9. 9.
    Muyldermans S. 2013. Nanobodies: Natural singledomain antibodies. Annu. Rev. Biochem. 82, 775–797.CrossRefPubMedGoogle Scholar
  10. 10.
    Pluckthun A. 2015. Designed ankyrin repeat proteins (DARPins): Binding proteins for research, diagnostics, and therapy. Annu. Rev. Pharmacol. Toxicol. 55, 489–511.CrossRefPubMedGoogle Scholar
  11. 11.
    Barrett D.M., Singh N., Porter D.L., et al. 2014. Chimeric antigen receptor therapy for cancer. Annu. Rev. Med. 65, 333–347.CrossRefPubMedGoogle Scholar
  12. 12.
    Abbasi J. 2017. Amid FDA approval filings, another CAR-T therapy patient death. J. Am, med. Assoc. 317, 2271.Google Scholar
  13. 13.
    Hansel T.T., Kropshofer H., Singer T., et al. 2010. The safety and side effects of monoclonal antibodies. Nat. Rev. Drug Discov. 9, 325–338.CrossRefPubMedGoogle Scholar
  14. 14.
    van Schouwenburg P.A., Rispens T., Wolbink G.J. 2013. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat. Rev. Rheumatol. 9, 164–172.CrossRefPubMedGoogle Scholar

Copyright information

© Pleiades Publishing, Inc. 2017

Authors and Affiliations

  • D. V. Kuprash
    • 1
    • 2
  • F. Yu. Garib
    • 2
    • 3
    • 4
  • S. A. Nedospasov
    • 1
    • 2
  1. 1.Engelhardt Institute of Molecular BiologyRussian Academy of SciencesMoscowRussia
  2. 2.Department of ImmunologyBiological Faculty, Moscow State UniversityMoscowRussia
  3. 3.Department of ImmunologyRussian Medical Academy of Postgraduate EducationMoscowRussia
  4. 4.Department of Clinical Immunology and AllergologySechenov First Moscow State Medical InstituteMoscowRussia

Personalised recommendations